Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer

Phase 1

Not yet recruiting

Conditions: Advanced Gastric Cancer

Interventions: Drug: Adebrelimab + Apatinib + Lrinotecan liposome

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-19

Lead Sponsor: Xianglin Yuan

Target Recruit Count: 66

Registration Number: NCT06592287

Locations: 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp;amp; Technology, Wuhan, Hubei, China

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Phase 2

Not yet recruiting

Conditions: Untreated Early-stage or Locally Advanced Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Adebrelimab

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06592625

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer

Interventions: Drug: adebrelimab and chemotherapy

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT06562920

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Phase 2

Not yet recruiting

Conditions: Solid Tumor

Interventions: Drug: Adebrelimab
Drug: Apatinib
Procedure: microwave ablation

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Beidahuang Industry Group General Hospital

Target Recruit Count: 60

Registration Number: NCT06537505

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

Phase 2

Recruiting

Conditions: Pancreatic Cancer Metastatic to Liver

Interventions: Drug: Irinotecan liposome
Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Calcium folinate

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Jiang Long

Target Recruit Count: 40

Registration Number: NCT06531278

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Chemotherapy, Bevacizumab, Adebrelimab

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06513221

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Phase 2

Recruiting

Conditions: Biomarkers
Esophageal Squamous Cell Carcinoma
Immunotherapy

Interventions: Drug: adebrelimab

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 48

Registration Number: NCT06510660

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: albumin paclitaxel
Drug: Nedaplatin

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-18

Lead Sponsor: Harbin Medical University

Target Recruit Count: 65

Registration Number: NCT06508229

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Phase 2

Recruiting

Conditions: Adebrelimab (SHR-1316)
XELOX
GC/GEJC

Interventions: Drug: Adebrelimab
Drug: XELOX

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 25

Registration Number: NCT06506292

Locations: 🇨🇳
Tianjin Cancer Institute and Hospital, Tianjin, Tianjin, China

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide

First Posted Date: 2024-07-15

Last Posted Date: 2024-07-15

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 48

Registration Number: NCT06500208

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy